MedicalCV drops heart valves in favour of AF (atrial fibrillation)
This article was originally published in Clinica
Executive Summary
MedicalCV has decided to shift from the mechanical heart valves it has made for more than 20 years and focus instead on the faster-growing atrial fibrillation market. The Minneapolis, Minnesota company has struggled in an increasingly competitive valve market, and has reported "significant losses on modest revenues".
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.